KMT2C Deficiency Drives the Transdifferentiation of Double-Negative Prostate Cancer to Confer Resistance to AR-Targeted Therapy

Published: 10 March 2025| Version 1 | DOI: 10.17632/bsn9c23y8k.1
Contributor:
jiacheng guo

Description

WB, IF and IHC images for this paper

Files

Categories

Cancer

Licence